Abacavir (Ziagen): News
- Approval of Generic Abacavir Tablets, 300 mg (June 20, 2012)
From U.S. Food and Drug Administration
- FDA Finds No Heart Attack Risk With HIV Drug (March 2, 2011)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Ongoing Abacavir Safety Review Finds No Increased Risk of Heart Attack (March 1, 2011)
From U.S. Food and Drug Administration
- Why Is Ziagen Associated With Heart Attacks in Some People? New Study Offers Possible Explanation (September 30, 2009)
From aidsmap.com
- Ziagen 300 mg Scored Tablet Facilitates Pediatric Treatment of Infection With HIV (December 19, 2008)
From U.S. Food and Drug Administration
- GlaxoSmithKline Announces New Program to Provide Financial Assistance for Eligible HIV Patients in the U.S. (November 11, 2008)
If you live in the United States, use private health insurance and take Combivir (AZT/3TC), Epzicom (abacavir/3TC, Kivexa), Lexiva (fosamprenavir, Telzir) or another HIV drug made by GlaxoSmithKline, you may have a chance to save a nice chunk of change.
From GlaxoSmithKline
- Important Safety-Related Label Update for Ziagen (Abacavir Sulfate) (July 18, 2008)
From U.S. Food and Drug Administration
- Ziagen's Heart Attack Link: How Long Has Glaxo Known? (May 12, 2008)
In The Independent
- Guidelines Panel Responds to Abacavir Data (April 10, 2008)
From Project Inform
- Early Communication About an Ongoing Safety Review of Ziagen (Abacavir) and Videx (Didanosine) (March 27, 2008)
From U.S. Food and Drug Administration
- Ziagen Pills Found in Fake Combivir Packaging (March 29, 2007)
To read PDF, click here.
From GlaxoSmithKline
- Two New Fixed-Dose Combinations Approved (August 2, 2004)
From U.S. Food and Drug Administration
- Drug Development News: Fixed-Dose Combinations (May/June 2004)
The Food and Drug Administration's fast-track approval process for fixed-dose combinations is about to bear fruit.
In GMHC Treatment Issues, from Gay Men's Health Crisis
- Combivir/Abacavir Drug Label Switch (Summer/Autumn 2002)
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- New Warnings About Hypersensitivity to Ziagen (Abacavir) (September 7, 2000)
In STEP Ezine, from Seattle Treatment Education Project
- Ziagen (Abacavir): New Warning on Restarting (August 4, 2000)
In AIDS Treatment News, from AIDS Treatment News
- Important Drug Warning: Severe Hypersensitivity Reactions Following Reintroduction With Ziagen (Abacavir Sulfate) Products (July 2000)
From U.S. Food and Drug Administration
- Hypersensitivity Reaction and Abacavir (Ziagen) (April 2000)
In What's New, from Project Inform
- Abacavir Warning: Certain Respiratory Symptoms Can Indicate Hypersensitivity Reaction (February 18, 2000)
From AIDS Treatment News
- Treatment Briefs: Changes in Warning on Abacavir Hypersensitivity (Winter 1999/2000)
In GMHC Treatment Issues, from Gay Men's Health Crisis
- Ziagen (Abacavir) Approved: Caution Essential (January 8, 1999)
From AIDS Treatment News
|
Advertisement
|
Email
Glossary
